Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.52 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353365 | 0.92 | FFAR1 (0.55) | FFAR1FFAR4PPARDMRGPRX4 | |
| SCHEMBL2350155 | 0.90 | FFAR1 (0.57) | FFAR1FFAR4PPARDEGFRERBB2 | |
| SCHEMBL2346125 | 0.90 | FFAR1 (0.59) | FFAR1FFAR4PPARDMRGPRX4 | |
| SCHEMBL2350166 | 0.89 | FFAR1 (0.64) | FFAR1FFAR4PPARDMRGPRX4 | |
| SCHEMBL2354053 | 0.89 | FFAR1 (0.56) | FFAR1FFAR4PPARD | |
| SCHEMBL2347172 | 0.89 | FFAR1 (0.56) | FFAR1FFAR4PPARDMRGPRX4 | |
| SCHEMBL2350445 | 0.89 | FFAR1 (0.55) | FFAR1FFAR4PPARDEGFRERBB2 | |
| SCHEMBL2349116 | 0.89 | FFAR1 (0.57) | FFAR1FFAR4PPARDMRGPRX4 | |
| SCHEMBL12394649 | 0.89 | FFAR1 (0.53) | FFAR1FFAR4FDFT1S1PR1S1PR5 | |
| SCHEMBL2346121 | 0.88 | FFAR1 (0.53) | FFAR1FFAR4PPARDMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1688138-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2006-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167378-A1 | Receptor Function Regulation Agent | GPR119, INSR, GPR88 | FFAR1 16/4885FFAR4 17/4885FDFT1 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.